When the drugs (don’t) work: The role of science in product commercialization

Paul-Emmanuel Anckaert

Research Policy, 2025, vol. 54, issue 5

Abstract: While the relationship between science and firms’ innovation performance has been extensively studied, little is known about how the nature of scientific input affects successful product commercialization. This paper aims to address this gap by analyzing data linking scientific publications to the eventual product market outcomes of early-stage drug candidates in the pharmaceutical industry. Examining the basic and applied nature of the scientific knowledge base underlying 5,613 early-stage drug candidates from 1995 to 2008, I find that despite the importance of advances made in basic science, its predictive and abstract outcomes on their own are unlikely to foster the development of drug candidates that achieve market approval. The substantial gap between the predictive rules from basic research and the unpredictable outcomes that emerge in variable states of human physiology, seems to limit the extent to which fundamental insights from basic science reduce the uncertainty related to the complexity of the human body in the real-world environment. In contrast, I show that early-stage drug candidates that combine fundamental insights from basic research and contextualized insights from applied science are significantly more likely to achieve market approval. This effect is particularly pronounced when these drugs have a more novel character and when firms leverage their own contextualized insights in the development of these drugs.

Keywords: Product commercialization; Science and innovation; Science translation; Pharmaceutical industry; Drug development (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0048733325000666
Full text for ScienceDirect subscribers only

Related works:
Working Paper: When the drugs (don’t) work: The role of science in product commercialization (2025)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:respol:v:54:y:2025:i:5:s0048733325000666

DOI: 10.1016/j.respol.2025.105237

Access Statistics for this article

Research Policy is currently edited by Anna Bergek, PhD, Alex Coad, PhD, Maryann Feldman, Elisa Giuliani, Adam B. Jaffe, Martin Kenney, Keun Lee, PhD, Ben Martin, MA, MSc, Kazuyuki Motohashi, Paul Nightingale, Ammon Salter, Maria Savona, Reinhilde Veugelers and John Walsh

More articles in Research Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu ().